Yahoo May Look to A...
Health Care: Drugs
ImmunoCellular Therapeutics Limited (IMUC: AMEX)
$2.56 -0.01 | -0.39%
05/17/13 - 04:01 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 2.56 |
| 52 Week High | 3.96 |
| 52 Week Low | 1.51 |
| Avg. Daily Vol. (Mil) | 0.48 |
| Beta (3 year) | 1.37 |
| Share Related Items | |
| Mkt Cap (Mil) | 134.98 |
| Shares Out (Mil) | 52.73 |
| Float (Mil) | 51.48 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 20.00 |
| Current Ratio | 21.50 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 0.00 |
| Price/Book | 7.32 |
| Price/Cash Flow | -6.80 |
| Per Share Data | |
| Earnings | -0.16 |
| Sales | 0.00 |
| Book Value | 0.35 |
| Cash Flow | -0.38 |
| Business Summary | |
|---|---|
| ImmunoCellular Therapeutics Limited is a clinical-stage biotechnology company that develops immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. | |
| General Information | |
| 21900 Burbank Boulevard
3rd Floor Woodland Hills, CA 91367 |
|
| www.imuc.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 5 | |
| CEO: Mr. Andrew Gengos | |
| Short Interest | |
| Current Month (Mil) | 3.93 |
| Previous Month (Mil) | 3.69 |
| Short Interest Ratio (Days) | 8.40 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -77.70 |
| Return on Investments | -105.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with IMUC
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- UserBiotech88
- ContributorStocks Under-$10 Setting Up...
Latest IMUC Headlines from TheStreet
- Biotech Stock Mailbag: Celldex, TG Therapeutics, Sarepta 03.08.13 | 06:03 am
- Biotech Stock Mailbag: Dynavax, ImmunoCellular, Celldex and Medgenics 02.08.13 | 06:02 am
- 3 Stocks Under $5 Making Big Moves 02.05.13 | 02:02 pm
- The Twitterverse's Biotech Stock Picks for 2013 01.02.13 | 08:01 am
- Biotech Stock Mailbag: Keryx, Amarin, ImmunoCellular 06.08.12 | 09:06 am
- 5 Stocks Under $10 Set to Soar 06.01.12 | 11:06 am
- 5 Stocks Under $10 Set to Soar 12.31.69 | 07:12 pm
Press Releases for IMUC
- ImmunoCellular Therapeutics To Present At Future Leaders Conference On April 5th - Business Wire 03.28.13 | 06:03 am
- ImmunoCellular Therapeutics To Present At ROTH Conference On March 18th - Business Wire 03.11.13 | 04:03 pm
- ImmunoCellular Therapeutics Announces Fourth Quarter And Full Year 2012 Financial Results - Business Wire 03.05.13 | 04:03 pm
- ImmunoCellular Therapeutics Announces Issuance Of Key Patent For ICT-121 Cancer Vaccine - Business Wire 03.04.13 | 06:03 am
- ImmunoCellular Therapeutics To Report Financial Results For The Fourth Quarter And Full Year 2012 On March 5, 2013 - Business Wire 02.26.13 | 06:02 am
- ImmunoCellular Therapeutics To Present At BIO CEO & Investor Conference On February 11th - Business Wire 02.04.13 | 04:02 pm
- ImmunoCellular Therapeutics’ Investigational New Drug (IND) Application For ICT-140 Allowed By The FDA - Business Wire 01.29.13 | 06:01 am
- ImmunoCellular Therapeutics Provides Update On Corporate Milestones - Business Wire 01.07.13 | 06:01 am
- ImmunoCellular Therapeutics Appoints Gary S. Titus To Its Board Of Directors - Business Wire 01.02.13 | 06:01 am
- ImmunoCellular Therapeutics Appoints Andrew Gengos As Chief Executive Officer - Business Wire 12.03.12 | 04:12 pm
Partner Headlines for IMUC
- ImmunoCellular Update Adds Clarity And Further Validates Investment Thesis - Seeking Alpha 03.07.13 | 09:03 am
- ImmunoCellular Therapeutics: An Opportunity For Great Upside Potential - Seeking Alpha 11.21.12 | 08:11 am
- ImmunoCellular Therapeutics Announces Pricing of its Previously Announced Public Offering of Common Stock and Warrants - Benzinga 10.18.12 | 09:10 am
- A Gold Mine In Biotechnology: The Companies Poised To Benefit - Seeking Alpha 09.04.12 | 09:09 am
- Reassessing & Continuing To Monitor Portfolios For Success - Seeking Alpha 07.30.12 | 09:07 am
- ImmunoCellular Provides Update on Phase II Clinical Trial of ICT-107 for Treatment of Glioblastoma - Benzinga 07.02.12 | 09:07 am
- MLV & Co Reiterates Buy, $4.50 PT on ImmunoCellular Therapeutics on Move to NYSE - Benzinga 05.25.12 | 12:05 pm
- Zacks Bull and Bear of the Day Highlights: ImmunoCellular, Willis Group Holdings, Encana, Exxon Mobil and Cenovus Energy - Press Releases - Zacks 02.21.12 | 09:02 am
- ImmunoCellular (IMUC) - Bull of the Day - Zacks 02.21.12 | 01:02 am
- Biotechs to Watch at the 2012 San Francisco Healthcare Confrences - Analyst Blog - Zacks 01.09.12 | 07:01 am
